Global Neuroendocrine Tumor Drug Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Neuroendocrine Tumor Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Product
  • 1.4.2 mTOR protein inhibitors
  • 1.4.3 Tyrosine kinase 3 inhibitors
  • 1.4.4 Somatostatin receptor antagonists
  • 1.4.5 Growth hormone releasing factor antagonists
  • 1.4.6 Somatostatin receptor agonists
  • 1.4.7 Others
• 1.5 Market by End User
  • 1.5.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Neuroendocrine Tumor Drug Market Size
  • 2.1.1 Global Neuroendocrine Tumor Drug Revenue 2014-2025
  • 2.1.2 Global Neuroendocrine Tumor Drug Sales 2014-2025
• 2.2 Neuroendocrine Tumor Drug Growth Rate by Regions
  • 2.2.1 Global Neuroendocrine Tumor Drug Sales by Regions
  • 2.2.2 Global Neuroendocrine Tumor Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Neuroendocrine Tumor Drug Sales by Manufacturers
  • 3.1.1 Neuroendocrine Tumor Drug Sales by Manufacturers
  • 3.1.2 Neuroendocrine Tumor Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Neuroendocrine Tumor Drug Revenue by Manufacturers
  • 3.2.1 Neuroendocrine Tumor Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Neuroendocrine Tumor Drug Price by Manufacturers
• 3.4 Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Neuroendocrine Tumor Drug Sales by Product
• 4.2 Global Neuroendocrine Tumor Drug Revenue by Product
• 4.3 Neuroendocrine Tumor Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Neuroendocrine Tumor Drug Breakdown Data by End User

6 North America

• 6.1 North America Neuroendocrine Tumor Drug by Countries
  • 6.1.1 North America Neuroendocrine Tumor Drug Sales by Countries
  • 6.1.2 North America Neuroendocrine Tumor Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Neuroendocrine Tumor Drug by Product
• 6.3 North America Neuroendocrine Tumor Drug by End User

7 Europe

• 7.1 Europe Neuroendocrine Tumor Drug by Countries
  • 7.1.1 Europe Neuroendocrine Tumor Drug Sales by Countries
  • 7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Neuroendocrine Tumor Drug by Product
• 7.3 Europe Neuroendocrine Tumor Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Neuroendocrine Tumor Drug by Countries
  • 8.1.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Countries
  • 8.1.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Neuroendocrine Tumor Drug by Product
• 8.3 Asia Pacific Neuroendocrine Tumor Drug by End User

9 Central & South America

• 9.1 Central & South America Neuroendocrine Tumor Drug by Countries
  • 9.1.1 Central & South America Neuroendocrine Tumor Drug Sales by Countries
  • 9.1.2 Central & South America Neuroendocrine Tumor Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Neuroendocrine Tumor Drug by Product
• 9.3 Central & South America Neuroendocrine Tumor Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Neuroendocrine Tumor Drug by Countries
  • 10.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Countries
  • 10.1.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Neuroendocrine Tumor Drug by Product
• 10.3 Middle East and Africa Neuroendocrine Tumor Drug by End User

11 Company Profiles

• 11.1 Eisai
  • 11.1.1 Eisai Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
  • 11.1.5 Eisai Recent Development
• 11.2 Exelixis, Inc.
  • 11.2.1 Exelixis, Inc. Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
  • 11.2.5 Exelixis, Inc. Recent Development
• 11.3 Foresee Pharmaceuticals, LLC
  • 11.3.1 Foresee Pharmaceuticals, LLC Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
  • 11.3.5 Foresee Pharmaceuticals, LLC Recent Development
• 11.4 Hutchison MediPharma Limited
  • 11.4.1 Hutchison MediPharma Limited Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
  • 11.4.5 Hutchison MediPharma Limited Recent Development
• 11.5 Intezyne, Inc
  • 11.5.1 Intezyne, Inc Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
  • 11.5.5 Intezyne, Inc Recent Development
• 11.6 INVENT Pharmaceuticals, Inc.
  • 11.6.1 INVENT Pharmaceuticals, Inc. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
  • 11.6.5 INVENT Pharmaceuticals, Inc. Recent Development
• 11.7 Ipsen S.A.
  • 11.7.1 Ipsen S.A. Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
  • 11.7.5 Ipsen S.A. Recent Development
• 11.8 Jiangsu Hengrui Medicine Co., Ltd.
  • 11.8.1 Jiangsu Hengrui Medicine Co., Ltd. Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
  • 11.8.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
• 11.9 Karyopharm Therapeutics, Inc.
  • 11.9.1 Karyopharm Therapeutics, Inc. Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
  • 11.9.5 Karyopharm Therapeutics, Inc. Recent Development
• 11.10 Lexicon Pharmaceuticals, Inc.
  • 11.10.1 Lexicon Pharmaceuticals, Inc. Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
  • 11.10.5 Lexicon Pharmaceuticals, Inc. Recent Development
• 11.11 Midatech Pharma Plc .
• 11.12 Millennium Pharmaceuticals, Inc.
• 11.13 MolMed S.p.A.
• 11.14 Northwest Biotherapeutics, Inc.
• 11.15 Novartis AG
• 11.16 OctreoPharm Sciences GmbH
• 11.17 OXiGENE, Inc.

12 Future Forecast

• 12.1 Neuroendocrine Tumor Drug Market Forecast by Regions
  • 12.1.1 Global Neuroendocrine Tumor Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Regions 2019-2025
• 12.2 Neuroendocrine Tumor Drug Market Forecast by Product
  • 12.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Product 2019-2025
• 12.3 Neuroendocrine Tumor Drug Market Forecast by End User
• 12.4 North America Neuroendocrine Tumor Drug Forecast
• 12.5 Europe Neuroendocrine Tumor Drug Forecast
• 12.6 Asia Pacific Neuroendocrine Tumor Drug Forecast
• 12.7 Central & South America Neuroendocrine Tumor Drug Forecast
• 12.8 Middle East and Africa Neuroendocrine Tumor Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Neuroendocrine Tumor Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details